Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
Subscribe To Our Newsletter & Stay Updated
